Treatment of malignant pleural effusion with the trifunctional antibody catumaxomab (Removab) (anti-EpCAM x Anti-CD3): results of a phase 1/2 study.

M, Sebastian; P, Kiewe; W, Schuette; D, Brust; C, Peschel; F, Schneller; KH, Rühle; G, Nilius; R, Ewert; S, Lodziewski; B, Passlick; W, Sienel; R, Wiewrodt; M, Jäger; H, Lindhofer; H, Friccius-Quecke; A, Schmittel

doi:10.1097/cji.0b013e318195b5bb

Public

Treatment of malignant pleural effusion with the trifunctional antibody catumaxomab (Removab) (anti-EpCAM x Anti-CD3): results of a phase 1/2 study.

Shared by NobleBlocks on Feb 1, 2009 • 12:00 AM UTC

Authors:

Sebastian M

Kiewe P

Schuette W

Abstract

Catumaxomab is a trifunctional monoclonal antibody consisting of a mouse immunoglobulin G2a part and a rat immunoglobulin G2b part with 2 different antigen binding sites binding the epithelial cell adhesion molecule antigen on tumor cells and CD3 on T lymphocytes. The intact Fc region provides a thi...

Discussions